帕博利珠单抗治疗微卫星高度不稳定/错配修复缺陷(MSI-H/dMMR)及非MSI-H/非dMMR晚期子宫内膜癌:2期KEYNOTE-158研究结果
KEYNOTE-158 2期研究更新了MSI-H/dMMR晚期子宫内膜癌(队列D,n=94)及非MSI-H/非dMMR晚期子宫内膜癌(队列D,n=96)接受帕博利珠单抗200 mg每3周一次、最多≥35个周期的结果。MSI-H/dMMR组客观缓解率为50%(95%CI 40%-61%),非MSI-H/非dMMR组为7%(95%CI 3%-14%)。结果继续支持帕博利珠单抗作为既往系统治疗后进展、不适合根治性手术或放疗的MSI-H/dMMR晚期子宫内膜癌患者的标准治疗选择。
要点
- MSI-H/dMMR晚期子宫内膜癌客观缓解率50%(95%CI 40%-61%),完全缓解16%、部分缓解34%。
- 非MSI-H/非dMMR晚期子宫内膜癌客观缓解率7%(95%CI 3%-14%),均为部分缓解。
- MSI-H/dMMR组中位无进展生存期13.1个月、中位总生存期65.4个月;非MSI-H/非dMMR组分别为2.1个月和11.1个月。
核心结论
- 这些结果继续支持帕博利珠单抗作为既往系统治疗后疾病进展、不适合根治性手术或放疗的MSI-H/dMMR晚期子宫内膜癌患者的标准治疗选择。
研究设计与样本
- 2期KEYNOTE-158研究(NCT02628067)报告了队列D(任何MSI/dMMR状态的晚期子宫内膜癌)和队列K(任何MSI-H/dMMR晚期实体瘤,除结直肠癌外)中MSI-H/dMMR子宫内膜癌患者更长随访的更新结果,以及队列D中非MSI-H/非dMMR晚期子宫内膜癌患者的首次结果。
- 患者接受帕博利珠单抗200 mg每3周一次,≥35个周期。
- 主要终点为中央审查按RECIST v1.1评估的客观缓解率;次要终点包括缓解持续时间、无进展生存期、总生存期和安全性。
- 截至2022年1月12日,MSI-H/dMMR组(n=94)中位(范围)随访54.5(14.7-71.4)个月,非MSI-H/非dMMR组(n=96)为68.3(64.3-71.9)个月。
主要发现
- MSI-H/dMMR组客观缓解率(95%CI)为50%(40%-61%);15例(16%)完全缓解,32例(34%)部分缓解。
- 非MSI-H/非dMMR组客观缓解率(95%CI)为7%(3%-14%);7例(7%)部分缓解,无完全缓解。
- 估计4年缓解持续时间率分别为66%和56%。
- MSI-H/dMMR组中位无进展生存期13.1(95%CI 4.3-25.7)个月,非MSI-H/非dMMR组2.1(95%CI 2.1-2.2)个月。
- MSI-H/dMMR组中位总生存期65.4(95%CI 29.5-未达到)个月,非MSI-H/非dMMR组11.1(95%CI 8.1-15.3)个月;两组毒性均可管理。
关键数值与推荐
- MSI-H/dMMR组客观缓解率50%(95%CI 40%-61%),完全缓解16%,部分缓解34%。
- 非MSI-H/非dMMR组客观缓解率7%(95%CI 3%-14%),部分缓解7%,无完全缓解。
- MSI-H/dMMR组估计4年缓解持续时间率66%,非MSI-H/非dMMR组56%。
- MSI-H/dMMR组中位无进展生存期13.1(95%CI 4.3-25.7)个月,非MSI-H/非dMMR组2.1(95%CI 2.1-2.2)个月。
- MSI-H/dMMR组中位总生存期65.4(95%CI 29.5-未达到)个月,非MSI-H/非dMMR组11.1(95%CI 8.1-15.3)个月。
临床怎么用
- 作者结论认为,这些结果继续支持帕博利珠单抗作为既往系统治疗后疾病进展、不适合根治性手术或放疗的MSI-H/dMMR晚期子宫内膜癌患者的标准治疗选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We report updated results with longer follow-up in patients with MSI-H/dMMR endometrial cancer (EC) in cohort D (advanced EC of any MSI/dMMR status) and cohort K (any MSI-H/dMMR advanced solid tumor, except colorectal) of the phase 2 KEYNOTE-158 study (NCT02628067) and the first results from patients with non-MSI-H/non-dMMR advanced EC (cohort D). METHODS: Patients received pembrolizumab 200 mg Q3W for ≥35 cycles. The primary endpoint was objective response rate (ORR) per RECIST v1.1 by central review. Secondary endpoints included duration of response (DOR), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: As of January 12, 2022, median (range) follow-up in the MSI-H/dMMR (n = 94) and non-MSI-H/non-dMMR (n = 96) groups was 54.5 (14.7-71.4) and 68.3 (64.3-71.9) months, respectively. The ORR (95 % CI) was 50 % (40 %-61 %) in the MSI-H/dMMR group; 15 patients (16 %) experienced a complete response, 32 (34 %) experienced a partial response. The ORR (95 % CI) in the non-MSI-H/non-dMMR group was 7 % (3 %-14 %); 7 patients (7 %) experienced a partial response, none experienced a complete response. The estimated 4-year DOR rates were 66 % and 56 %, respectively. Median PFS was 13.1 (95 % CI, 4.3-25.7) months in the MSI-H/dMMR group and 2.1 (95 % CI, 2.1-2.2) months in the non-MSI-H/non-dMMR group. Median OS was 65.4 (95 % CI, 29.5-not reached) and 11.1 (95 % CI, 8.1-15.3) months, respectively. Toxicity was manageable in both groups. CONCLUSIONS: These results continue to support pembrolizumab as a standard-of-care option for MSI-H/dMMR advanced EC in patients with disease progression following prior systemic therapy who are not candidates for curative surgery or radiation.
引用
- O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results. Gynecol Oncol. 2025. PMID: 39847999. doi:10.1016/j.ygyno.2024.12.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。